Phaedra Chrousos - 22 May 2024 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role
Director
Signature
/s/ Phaedra Chrousos
Issuer symbol
VNDA
Transactions as of
22 May 2024
Net transactions value
$0
Form type
4
Filing time
24 May 2024, 16:43:11 UTC
Previous filing
12 Jun 2023
Next filing
09 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Award $0 +21,887 +52% $0.000000 64,125 22 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNDA Stock Option (right to buy) Award $0 +40,202 $0.000000 40,202 22 May 2024 Common Stock 40,202 $5.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
F2 This option vests and becomes exercisable with respect to 100% of the option shares on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.